Skip to main content

Table 5 Comparison between hepatitis virology markers in the studied patients

From: Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

N = 200 At the start of treatment After 1 month of treatment At the end of treatment P-value
HCV Ab
Negative 0 0% 0 0% 0 0%
Positive 200 100% 200 100% 200 100%
HBs Ag
Negative 166 83% 159 79.5% 154 77% P1 = 0.439 NS
P2 = 0.064 NS
P3 = 0.279 NS
Positive 34 17% 41 20.5% 46 23%
HBs Ab
Negative 194 97% 194 97% 194 97% P1 = 1.0 NS
P2 = 1.0 NS
P3 = 1.0 NS
Positive 6 3% 6 3% 6 3%
HBc Ab
IgG
  Negative 165 82.5% 165 82.5% 164 82% P1 = 0.585 NS
P2 = 0.585 NS
P3 = 1.0 NS
  Positive 35 17.5% 35 17.5% 36 18%
IgM
  Negative 196 98% 193 % 189 94.5% P1 = 0.521 NS
P2 = 0.009 S
P3 = 0.043 S
  Positive 4 2% 7 3% 11 5.5%
HB e Ag
Negative 194 97% 194 97% 193 96.5% P1 = 0.759 NS
P2 = 0.778 NS
P3 = 0.557 NS
Positive 6 3% 6 3% 7 3.5%
HB e Ab
Negative 180 90% 178 89% 178 89% P1 = 0.744 NS
P2 = 0.744 NS
P3 = 1.0 NS
Positive 20 10% 22 11% 22 11%
  1. X2: chi-square test
  2. S: p-value < 0.05 is considered significant
  3. HS: p-value < 0.001 is considered highly significant
  4. P1: refers to the statistical difference between the start of DAA and 1 month after DAA
  5. P2: refers to the statistical difference between the start of DAA and the end of DAA
  6. P3: refers to the statistical difference between 1 month after DAA and the end of DAA